Chimeric antigen receptor T cell immunotherapy for sustained remission of double expression diffuse large B-cell lymphoma after the recurrence of autologous hematopoietic stem cell transplantation: report of one case and review of literature
10.3760/cma.j.cn115356-20190703-00130
- VernacularTitle:双表达弥漫大B细胞淋巴瘤自体造血干细胞移植复发后嵌合抗原受体T细胞免疫治疗持续缓解一例并文献复习
- Author:
Yuqi LIN
1
;
Xiangli CHEN
;
Yuzhu ZANG
;
Lei ZHANG
;
Wenhui ZHANG
;
Kai SUN
;
Yacai WANG
Author Information
1. 河南大学人民医院血液科，郑州 450003
- From:
Journal of Leukemia & Lymphoma
2020;29(5):288-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the therapeutic efficacy of chimeric antigen receptor T cell (CAR-T) for treatment of relapsed patients with double expression lymphoma after autologous hematopoietic stem cell transplantation (auto-HSCT).Methods:The treatment process of one patient with double expression diffuse large B-cell lymphoma who received CAR-T immunotherapy after the recurrence of auto-HSCT in Henan Provincial People's Hospital in August, 2017 was retrospectively analyzed, and the related literature was reviewed.Results:A 50-year-old female double expression diffuse large B-cell lymphoma patient received the standard treatment regimen, and then had auto-HSCT based on the BEAM preconditioning regimen. The patient relapsed after 5 months, and finally got sustained remission after chemotherapy regimen containing cladribine for 2 courses of treatment combined with CAR-T therapy. CD20 +-CAR-T cells were detected in this patient for 8 mouths sustainably. Conclusion:For relapsed patients with non-Hodgkin lymphoma after auto-HSCT, reduction remission of the treatment regimen containing cladribine followed by CAR-T sequential regimen may be a better treatment option.
